Pimavanserin use in a movement disorders clinic: a single-center experience

Abhimanyu Mahajan, Bisena Bulica, Ayesha Ahmad, Patricia Kaminski, Peter LeWitt, Danette Taylor, Shana Krstevska, Neepa Patel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Parkinson’s disease psychosis (PDP) is a disabling non-motor symptom of Parkinson’s disease (PD) that is challenging to treat. Dopamine receptor blockers (DRB) are used to treat PDP, though these may be associated with adverse effects, including worsening of Parkinsonism. Pimavanserin, a selective 5-HT2A receptor inverse agonist, was recently FDA-approved for treatment of PDP; however, there is limited information on its long-term use in PDP patients. Methods: A retrospective chart review of patients prescribed pimavanserin was performed in August, 2017. Data on demographics, psychotic features, sleep, and adverse effects was collected using a semi-structured telephone interview with patients or caregivers. Hallucination severity (HS) was quantified as mild (< 1 episode/week), moderate (1/week to < 1/day), or severe (daily/continuous). Results: Seventeen patients consented to participate in the study; 16 were diagnosed with PDP, 1 with Lewy body dementia. Fourteen had co-morbid cognitive impairment/dementia. The mean duration of Parkinsonism was 11.8 ± 8.0 years, with 2.6 ± 1.9 years of psychosis. Eleven of the seventeen patients reported improvement of hallucinations of which 5/8 were initiated on pimavanserin monotherapy, and 6/9 reported improvement of HS with combination of DRB. Six of nine patients prescribed DRB were able to discontinue this medication after introduction of pimavanserin. Four patients discontinued medications (2, no benefit; 1, spontaneous resolution; 1, cost). No major side effects were reported, and two patients noted subjective improvement of sleep. Conclusion: In our series based on a small sample size, pimavanserin is well-tolerated and effective as both monotherapy and adjuvant treatment for moderate to severe. This medication can facilitate reduction or cessation of DRB medication.

Original languageEnglish (US)
JournalNeurological Sciences
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Movement Disorders
Psychotic Disorders
Parkinson Disease
Dopamine Antagonists
Dopamine Receptors
Hallucinations
Parkinsonian Disorders
Sleep
Receptor, Serotonin, 5-HT2A
Lewy Body Disease
Pimavanserin
Sample Size
Caregivers
Dementia
Demography
Interviews
Costs and Cost Analysis
Therapeutics

Keywords

  • Hallucinations
  • Parkinson’s disease
  • Parkinson’s disease psychosis
  • Pimavanserin

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Pimavanserin use in a movement disorders clinic : a single-center experience. / Mahajan, Abhimanyu; Bulica, Bisena; Ahmad, Ayesha; Kaminski, Patricia; LeWitt, Peter; Taylor, Danette; Krstevska, Shana; Patel, Neepa.

In: Neurological Sciences, 01.01.2018.

Research output: Contribution to journalArticle

Mahajan, Abhimanyu ; Bulica, Bisena ; Ahmad, Ayesha ; Kaminski, Patricia ; LeWitt, Peter ; Taylor, Danette ; Krstevska, Shana ; Patel, Neepa. / Pimavanserin use in a movement disorders clinic : a single-center experience. In: Neurological Sciences. 2018.
@article{5913ac5082e04bd596dbc0b66cede4d4,
title = "Pimavanserin use in a movement disorders clinic: a single-center experience",
abstract = "Background: Parkinson’s disease psychosis (PDP) is a disabling non-motor symptom of Parkinson’s disease (PD) that is challenging to treat. Dopamine receptor blockers (DRB) are used to treat PDP, though these may be associated with adverse effects, including worsening of Parkinsonism. Pimavanserin, a selective 5-HT2A receptor inverse agonist, was recently FDA-approved for treatment of PDP; however, there is limited information on its long-term use in PDP patients. Methods: A retrospective chart review of patients prescribed pimavanserin was performed in August, 2017. Data on demographics, psychotic features, sleep, and adverse effects was collected using a semi-structured telephone interview with patients or caregivers. Hallucination severity (HS) was quantified as mild (< 1 episode/week), moderate (1/week to < 1/day), or severe (daily/continuous). Results: Seventeen patients consented to participate in the study; 16 were diagnosed with PDP, 1 with Lewy body dementia. Fourteen had co-morbid cognitive impairment/dementia. The mean duration of Parkinsonism was 11.8 ± 8.0 years, with 2.6 ± 1.9 years of psychosis. Eleven of the seventeen patients reported improvement of hallucinations of which 5/8 were initiated on pimavanserin monotherapy, and 6/9 reported improvement of HS with combination of DRB. Six of nine patients prescribed DRB were able to discontinue this medication after introduction of pimavanserin. Four patients discontinued medications (2, no benefit; 1, spontaneous resolution; 1, cost). No major side effects were reported, and two patients noted subjective improvement of sleep. Conclusion: In our series based on a small sample size, pimavanserin is well-tolerated and effective as both monotherapy and adjuvant treatment for moderate to severe. This medication can facilitate reduction or cessation of DRB medication.",
keywords = "Hallucinations, Parkinson’s disease, Parkinson’s disease psychosis, Pimavanserin",
author = "Abhimanyu Mahajan and Bisena Bulica and Ayesha Ahmad and Patricia Kaminski and Peter LeWitt and Danette Taylor and Shana Krstevska and Neepa Patel",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10072-018-3500-5",
language = "English (US)",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia",

}

TY - JOUR

T1 - Pimavanserin use in a movement disorders clinic

T2 - a single-center experience

AU - Mahajan, Abhimanyu

AU - Bulica, Bisena

AU - Ahmad, Ayesha

AU - Kaminski, Patricia

AU - LeWitt, Peter

AU - Taylor, Danette

AU - Krstevska, Shana

AU - Patel, Neepa

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Parkinson’s disease psychosis (PDP) is a disabling non-motor symptom of Parkinson’s disease (PD) that is challenging to treat. Dopamine receptor blockers (DRB) are used to treat PDP, though these may be associated with adverse effects, including worsening of Parkinsonism. Pimavanserin, a selective 5-HT2A receptor inverse agonist, was recently FDA-approved for treatment of PDP; however, there is limited information on its long-term use in PDP patients. Methods: A retrospective chart review of patients prescribed pimavanserin was performed in August, 2017. Data on demographics, psychotic features, sleep, and adverse effects was collected using a semi-structured telephone interview with patients or caregivers. Hallucination severity (HS) was quantified as mild (< 1 episode/week), moderate (1/week to < 1/day), or severe (daily/continuous). Results: Seventeen patients consented to participate in the study; 16 were diagnosed with PDP, 1 with Lewy body dementia. Fourteen had co-morbid cognitive impairment/dementia. The mean duration of Parkinsonism was 11.8 ± 8.0 years, with 2.6 ± 1.9 years of psychosis. Eleven of the seventeen patients reported improvement of hallucinations of which 5/8 were initiated on pimavanserin monotherapy, and 6/9 reported improvement of HS with combination of DRB. Six of nine patients prescribed DRB were able to discontinue this medication after introduction of pimavanserin. Four patients discontinued medications (2, no benefit; 1, spontaneous resolution; 1, cost). No major side effects were reported, and two patients noted subjective improvement of sleep. Conclusion: In our series based on a small sample size, pimavanserin is well-tolerated and effective as both monotherapy and adjuvant treatment for moderate to severe. This medication can facilitate reduction or cessation of DRB medication.

AB - Background: Parkinson’s disease psychosis (PDP) is a disabling non-motor symptom of Parkinson’s disease (PD) that is challenging to treat. Dopamine receptor blockers (DRB) are used to treat PDP, though these may be associated with adverse effects, including worsening of Parkinsonism. Pimavanserin, a selective 5-HT2A receptor inverse agonist, was recently FDA-approved for treatment of PDP; however, there is limited information on its long-term use in PDP patients. Methods: A retrospective chart review of patients prescribed pimavanserin was performed in August, 2017. Data on demographics, psychotic features, sleep, and adverse effects was collected using a semi-structured telephone interview with patients or caregivers. Hallucination severity (HS) was quantified as mild (< 1 episode/week), moderate (1/week to < 1/day), or severe (daily/continuous). Results: Seventeen patients consented to participate in the study; 16 were diagnosed with PDP, 1 with Lewy body dementia. Fourteen had co-morbid cognitive impairment/dementia. The mean duration of Parkinsonism was 11.8 ± 8.0 years, with 2.6 ± 1.9 years of psychosis. Eleven of the seventeen patients reported improvement of hallucinations of which 5/8 were initiated on pimavanserin monotherapy, and 6/9 reported improvement of HS with combination of DRB. Six of nine patients prescribed DRB were able to discontinue this medication after introduction of pimavanserin. Four patients discontinued medications (2, no benefit; 1, spontaneous resolution; 1, cost). No major side effects were reported, and two patients noted subjective improvement of sleep. Conclusion: In our series based on a small sample size, pimavanserin is well-tolerated and effective as both monotherapy and adjuvant treatment for moderate to severe. This medication can facilitate reduction or cessation of DRB medication.

KW - Hallucinations

KW - Parkinson’s disease

KW - Parkinson’s disease psychosis

KW - Pimavanserin

UR - http://www.scopus.com/inward/record.url?scp=85050188841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050188841&partnerID=8YFLogxK

U2 - 10.1007/s10072-018-3500-5

DO - 10.1007/s10072-018-3500-5

M3 - Article

C2 - 30032332

AN - SCOPUS:85050188841

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -